伴and is cosponsored by the University of Tennessee College
III IIIIIIIIIIIIIIIIIIIIIII - search.proquest.com
Anticoagulant therapy plays an important role in the prevention and treatment of arterial and
venous thrombosis Researchers and clinicians are becoming interested in using Factor Xa …
venous thrombosis Researchers and clinicians are becoming interested in using Factor Xa …
Factor Xa is a superior target to factor IIa for antithrombotic therapies
HR Büller - Seminars in thrombosis and hemostasis, 2003 - thieme-connect.com
At least five arguments can be put forward to support the concept that selective inhibitors of
factor Xa might be superior to selective inhibitors of thrombin. It should be noted, however …
factor Xa might be superior to selective inhibitors of thrombin. It should be noted, however …
Inhibition of factor Xa: a potential target for the development of new anticoagulants
JH Alexander, KP Singh - American journal of cardiovascular drugs, 2005 - Springer
Anticoagulant therapy plays an important role in the prevention and treatment of pathologic
arterial and venous thrombosis. There is increasing enthusiasm in the inhibition of Factor Xa …
arterial and venous thrombosis. There is increasing enthusiasm in the inhibition of Factor Xa …
Synthetic direct and indirect factor Xa inhibitors
MM Samama - Thrombosis research, 2002 - thrombosisresearch.com
Unfractionated heparin (UFH) inhibits both factor Xa and factor IIa in the presence of
antithrombin III or AT. Low molecular weight heparins (LMWH) have a potent factor Xa …
antithrombin III or AT. Low molecular weight heparins (LMWH) have a potent factor Xa …
New anticoagulants
J Harenberg, B Casu - Seminars in Thrombosis and …, 2007 - thieme-connect.com
Within recent years, considerable interest has arisen in the new anticoagulant and non–
anticoagulant actions of heparins and other glycosaminoglycans. In addition, oral direct …
anticoagulant actions of heparins and other glycosaminoglycans. In addition, oral direct …
Anticoagulant drugs: what is new?
A Kei, M Florentin, M Elisaf… - International Angiology: a …, 2011 - europepmc.org
Heparins and vitamin K antagonists have been the cornerstones of anticoagulation
treatment for several decades. Despite their effectiveness, these agents have limitations …
treatment for several decades. Despite their effectiveness, these agents have limitations …
The future of anticoagulation
DA Hoppensteadt, W Jeske, J Walenga… - … in respiratory and …, 2008 - thieme-connect.com
The conventional management of thrombotic disorders is based on the use of heparin, oral
anticoagulants, and aspirin. The development of low molecular weight heparins and the …
anticoagulants, and aspirin. The development of low molecular weight heparins and the …
Idraparinux sodium
M Diaz-Ricart, M del Fresno - Drugs of the Future, 2002 - access.portico.org
Activated factor Xa promotes coagulation by generating small amounts of thrombin in the
proximity of platelets, thus enhancing their activation, and by binding to factor Va on …
proximity of platelets, thus enhancing their activation, and by binding to factor Va on …
[引用][C] Factor Xa inhibitors as novel antithrombotic agents: facts and perspectives
B Kaiser, J Hauptmann - Cardiovascular drug reviews, 1994 - Wiley Online Library
In recent years, the understanding of the causes and mechanisms of thromboembolic
disorders has rapidly grown. The established therapeutic strategies obviously have their …
disorders has rapidly grown. The established therapeutic strategies obviously have their …
[引用][C] Management of Thrombotic
J Fareed, A Debra, D Fareed - Coronary …, 2005 - JAYPEE BROTHERS PUBLISHERS